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The mechanisms underlying the development and progression of psychiatric illnesses are only partially known. Clinical data
suggest blood-brain barrier (BBB) breakdown and inﬂammation are involved in some patients groups. Here we put forward
the “BBB hypothesis” and abnormal blood-brain communication as key mechanisms leading to neuronal dysfunction underlying
disturbed cognition, mood, and behavior. Based on accumulating clinical data and animal experiments, we propose that events
within the “neurovascular unit” are initiated by a focal BBB breakdown, and are associated with dysfunction of brain astrocytes,
a local inﬂammatory response, pathological synaptic plasticity, and increased network connectivity. Our hypothesis should
be validated in animal models of psychiatric diseases and BBB breakdown. Recently developed imaging approaches open the
opportunity to challenge our hypothesis in patients. We propose that molecular mechanisms controlling BBB permeability,
astrocytic functions, and inﬂammation may become novel targets for the prevention and treatment of psychiatric disorders.
Copyright © 2009 Hadar Shalev et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Structure and Function of
the Blood-Brain Barrier
More than a century ago, Ehrlich [1] demonstrated the
lack of permeability of intracerebral vessels to albumin-
binding dyes, which suggested the presence of a barrier to
proteins in the brain. Several years later, Lewandowsky [2]
suggested that the absence of central nervous system (CNS)
pharmacological actions of intravenously administered bile
acids or ferrocyanide was due to the blood-brain barrier
(BBB), a mechanical membrane that separates blood from
brain.
Three barrier layers regulate molecular exchange at
the interfaces between the blood and the neural tissue or
its ﬂuid spaces: the BBB formed by the cerebrovascular
endothelial cells between blood and brain interstitial ﬂuid,
thechoroidplexusepitheliumbetweenbloodandventricular
cerebrospinal ﬂuid (CSF), and the arachnoid epithelium
between blood and subarachnoid CSF. Since individual
neurons are extremely close to the brain capillaries, rarely at
a distance greater than 20μm, of the various CNS barriers,
the BBB exerts the greatest control over the immediate
microenvironment of brain cells [3]. The BBB is present
in the capillaries throughout the brain (for reviews see [4–
6]).ThecomponentscomposingtheBBBincludeendothelial
cells lining the lumen of brain capillaries, linked together
by tight junctions that are composed of speciﬁc proteins
(e.g., claudins, occludins, ZO-1, ZO-2, ZO-3, and cingulin—
see [7]), pinocytic vesicles, and speciﬁc transport mecha-
nisms. Surrounding the endothelial cells are the basement
membrane, brain pericytes, and astroglial foot processes—
creating a third continuous layer that separates these blood
vessels from the brain tissue. All of these components enable
the formation of a barrier that hinders the entry of most
molecules into the brain, and that is actively involved in
exporting such molecules out of the brain in case of penetra-
tion. With the exception of very small lipophilic molecules,
hydrophilic molecules enter the brain via active transport,
and speciﬁc transporters exist for required nutrients such as
glucose and certain amino acids.2 Cardiovascular Psychiatry and Neurology
2.Blood-Brain BarrierBreakdown inDiseases
In numerous pathologies of the brain, and also in other
vascular, inﬂammatory, and infectious diseases, the function
of the BBB is often compromised [3]. For example, the
capillaries of many glial tumors are leaky compared to those
of normal brain tissue, either as a result of a lack of inductive
factors, or owing to the release of permeability factors such
as vascular endothelial growth factor (VEGF). Moreover, the
tight junction protein claudin 3 is downregulated in some
brain tumors [8]. In addition, evidence for the loss of agrin
from the abluminal surface of the endothelial cells adjacent
to astrocytic endfeet [9] may contribute to BBB damage
in Alzheimer’s disease [10] and to the redistribution of
astrocytic Aquaporin 4 (AQP4) in glioblastomas [11]. AQP4
and inward rectifying potassium channels (KIR4.1) are often
downregulated in BBB breakdown [12] and may contribute
tothelackofhomeostasisforwaterandpotassiummolecules
(describedhereafter).Someneuropathologies,suchasmulti-
ple sclerosis and epilepsy, may involve an early phase of BBB
disturbance that precedes the disorganization and damage of
the neuronal network, suggesting that vascular damage and
increased BBB permeability can lead to secondary neuronal
disorders [13–15]. In epilepsy, the normal pattern of brain
ATP-binding cassette (ABC) transporters expression may
also change, with upregulation of P-glycoprotein (Pgp) on
astrocytes and the brain endothelium [16]; this may lead
to the eﬄux of antiepileptic drugs from the brain into
the vascular compartment and contribute to a pharmacore-
sistent disease. Kortekaas et al. [17] showed an elevated
uptake of the Pgp substrate [11C]verapamil using positron
emission tomography (PET) in the midbrain of patients
with Parkinson’s disease, which is consistent with disturbed
Pgp function in the BBB. In animal models of Alzheimer’s
disease, amyloid-β (Aβ) accumulation is often ﬁrst seen in
close proximity to blood vessels, with toxicity on endothe-
lium and astrocytes observed before signiﬁcant neuronal loss
[18]. The ability of agents released during inﬂammation
to increase the permeability of the brain endothelium has
been described. Activation of endothelial bradykinin B2
receptors causes an increase in intracellular Ca2+ concen-
trations and tight junctions opening and may underlie BBB
opening in conditions in which intravascular coagulation
occurs. In addition, bradykinin can activate NF-κBp a t h w a y
in astrocytes, leading to the release of interleukin-6 (IL-
6), which can amplify the eﬀect by acting back on the
endothelium[19].Tumornecrosisfactor-α(TNFα)increases
BBB permeability by direct action on the endothelium [20]
and indirectly via endothelin 1 production and IL-1β release
from astrocytes [21]. During injury, several substances are
released from central and peripheral neurons, connective
tissue, cells, and blood cells. Many of these substances,
such as matrix metaloproteases, substance P, calcitonin gene-
related peptide (CGRP), serotonin, histamine, and ATP, can
aﬀect BBB permeability. For example, the release of IL-1β
leads to a decreased concentration or altered localization
of the tight junction protein occludin, and increases BBB
permeability. TNFα, histamine and interferon-γ released
in inﬂammatory pain can also cause changes in brain
endothelial permeability [22]. Massive neuronal activation,
as observed under spreading depolarization, may induce
upregulation and release of metaloproteases causing BBB
breakdown [23].
3. From BBB Breakdown to Psychopathology
We hypothesize that a primary vascular pathology, leading to
BBB breakdown, will result in the leakage of serum-derived
vascular components into the brain tissue and may cause
brain dysfunction which, under some conditions (extent,
duration, and/or location), will result in disturbed thinking
processes,mood,andbehavior—suchasthosecharacterizing
psychiatric patients. Here we will present clinical evidence
for BBB pathology in psychiatric patients and hypothesize
potential mechanisms linking altered vascular permeability
to psychopathology.
3.1. Clinical Evidence. Clinical evidence for BBB breakdown
in patients with psychopathology is insuﬃcient. However,
accumulating data strongly suggest the existence of BBB
pathology in a subset of patients with major psychiatric
illnesses, including depression and schizophrenia. The main
diﬃculties are, on the one hand, the lack of a routine,
quantitative, and reproducible comprehensive method for
measuring BBB permeability in human, and on the other
hand, the lack of reliable and widely accepted animal models
for human psychiatric illnesses.
Qualitative evaluation of BBB disruption in patients is
most frequently conducted using common brain imaging
modalities, such as magnetic resonance imaging (MRI),
computerizedtomography(CT),andsinglephotonemission
CT (SPECT), following the peripheral administration of
nonpermeable contrast agents [24]. Extravascular accu-
mulation of the contrast agent indicates BBB breakdown.
Although CT and MRI are the best available methods for
studying anatomical brain lesions and are most often used
as diagnostic tools (mainly to exclude other pathologies) in
psychiatricpatients,thecurrentlyusedimagingprotocolsare
relatively insensitive in detecting small changes in contrast
agent accumulation (e.g., as compared with SPECT [25]).
Bilateralcontrast(gadolinium)enhancementofthetemporal
lobes in the region of the amygdala and hippocampus
has been reported in a case report of a patient with
progressive insomnia, short-term memory loss, depression,
and cognitive impairment due to paraneoplastic syndrome
[26]. In order to increase method sensitivity and allow
quantiﬁcation of BBB permeability, several methods has
recently been developed using dynamic contrast enhanced
imaging (e.g., [27, 28], and see also the review by Zaharchuk
[29]). These methods have not yet become available for
routine clinical examinations, and published studies relate
a relatively small number of patients with brain tumors or
posttraumatic epilepsy. To this end, there are no published
studies in psychiatric patients.
Quantitative evaluation of BBB functioning in the
clinical setting can also be obtained using analysis of the
cerebrospinal ﬂuid (CSF) for serum proteins (e.g., albumin)Cardiovascular Psychiatry and Neurology 3
or plasma analysis of brain constituents (e.g., S100B, [30]).
However, neither of these measures is routinely assessed
in patients, and only incomplete data from small clinical
studies are available. BBB dysfunction has been indicated
in a subgroup of schizophrenic patients by measuring
increased albumin and IgG CSF levels [31, 32]. Muller and
Ackenheil [31] further showed an association between CSF-
serum albumin ratio and the patients’ negative symptoms.
CSF-serum albumin ratio was also found to be higher in
elderly depressed women [33] and in patients suﬀering from
dementias compared to age-matched controls [34]. Interest-
ingly,nondementedwomenwhodevelopeddementiaduring
the research follow-up had an initial higher CSF-serum
albumin ratio compared to those who did not develop the
disease, suggesting BBB dysfunction may precede the clinical
symptoms and be related to the pathogenesis of the disease.
Theseclinicalstudiesaresupportedbymorphologicalstudies
demonstrating abnormalities in cerebral capillaries that
bear BBB functions. These include degeneration and focal
necrotic changes of the endothelium, vascular basement
membrane alterations accompanied by accumulation of
collagen ﬁbrils, decreased mitochondrial content, as well
as increased pinocytotic vesicles and loss of tight junctions
[35, 36].
S100B is primarily a brain-speciﬁc, astrocytic calcium
binding protein involved in intracellular signal transduction.
Information about the functional implication of S100B
secretion by astrocytes is scant, but accumulating evidence
suggests it exerts trophic or toxic eﬀects depending on
its concentration [37]. Accumulating data from clinical
studies convincingly demonstrate increased S100B levels
in the serum of patients suﬀering from acute or chronic
schizophrenia as well as depression [38, 39]. The observed
increase in plasma levels of S100B may reﬂect increased
BBB permeability [30]. However, increased plasma levels of
S100B may also be due to increased production and/or active
secretion from glia cells, or to their destruction [40, 41].
3.2. BBB-Induces Astrocytic Transformation and Dysfunction.
Astrocytic end-feet surrounding capillaries in the central
nervous system have a role in regulating tight junction
expression [42], and are considered an integral part of the
BBB. However, BBB breakdown results in a rapid (within
hours) transformation of the normally occurring “resting
astrocytes”into“active”ones[13].Whilethesignalingmech-
anisms underlying astrocytic transformation in the injured
brain are not known, recent experimental evidence indicates
that extravasation of the most abundant serum protein,
albumin, into the neuropil may serve as the key factor for
astrocytic transformation via the transforming growth factor
beta (TGFβ) signaling pathway. Transformed astrocytes are
observed in ischemic, inﬂammatory, and traumatic brain
injuries and are often the only pathological change observed
in the epileptic brain. Transformed astrocytes are charac-
terized by a robust change in gene expression that includes
the upregulation of GFAP and S100B, downregulation of
glutamatetransportersandglutaminesynthase,aswellasthe
inward rectifying potassium channel, KIR4.1, AQP4, and gap
junctions’ proteins (see [43] and unpublished data). These
robust changes in gene expression predict a dysregulation
in homeostasis of the extracellular environment, speciﬁcally
increased concentrations of potassium and glutamate—
which are increased with neuronal activity and strongly
aﬀect their excitability [12, 43]. In addition, experimental
evidence indicates that transformed astrocytes upregulate
the expression of cytokines and are part of the local
inﬂammatory brain response (described hereafter).
Is there evidence for the transformation of astrocytes in
the brains of psychiatric patients? Brain injuries that often
involve BBB breakdown and astrocytic response increase
the risk for signiﬁcant neuropsychiatric sequelae, including
personality changes, depression, anxiety, dementia, and
perhaps psychosis [44, 45]. The hypothalamic-pituitary-
adrenal (HPA) axis is activated by stress, and its activity is
seen under acute and chronic stress conditions, including
mental and physiological distress. Stress activates the HPA
axis through the release of corticotropin-releasing hormone
(CRH), leading to secretion of catecholamines and glucocor-
ticoids. CRH has proinﬂammatory eﬀects that are mediated
throughmastcells,whichregulateBBBpermeability.Indeed,
stress has been shown to induce BBB breakdown [46, 47],
whichcanbeblockedbypretreatmentwiththeCRHreceptor
antagonist antalarmin [48]. Interestingly, antalarmin has
been also shown to block stress-induced behavioral changes.
Recently, direct evidence support the presence of an
astrocytic response in the brains of psychiatric patients even
with no obvious preceding injury. Most studies based the
“astrocytic hypothesis” of schizophrenia and depression on
increasedserumorCSFlevelsoftheastrocyticS100Bprotein.
In summarizing the results of clinical studies, reports
consistently show increased S100B levels in patients suﬀering
from schizophrenia in both the acute and chronic psychotic
stages of disease. Furthermore, this increase remains in those
patients who develop a residual state with relevant negative
symptoms, whereasS100B normalizes in recovering patients.
Neuroleptic medication most likely cannot be regarded as a
confounding factor, as these ﬁndings have been reported in
nonmedicated patients as well (for review, see [41]). While
these studies did not diﬀerentiate between increased S100B
productionandincreasedBBBpermeabilityforS100B(when
measured in serum), in a recent histological study Steiner et
al. [49] analyzed the cell-density of S100B-immunopositive
glia in diﬀerent brain regions (including the anterior cingu-
late, dorsolateral prefrontal (DLPF), orbitofrontal, superior
temporal cortex, and hippocampus) of 18 patients with
schizophrenia (16 matched controls). They reported that
cortical brain regions contained signiﬁcantly more S100B-
immunopositive glia in the schizophrenia group compared
to controls. This eﬀect was pronounced in the paranoid
schizophrenia subgroup and particularly in the DLPF brain
area. Glial pathology has also recently been demonstrated in
mood disorders. In a combined clinical study and a meta-
analysis of published studies on S100B involving 193 patients
suﬀering from mood disorders and 132 healthy controls
[39], the authors concluded that serum levels of S100B are
consistently elevated during acute major depressive or manic
episodes. Additionally, it is demonstrated that serum S100B4 Cardiovascular Psychiatry and Neurology
decreases reliably during antidepressive treatment together
with clinical improvement.
3.3. BBB Breakdown, Astrocytic Transformation, and Brain
Inﬂammation. Thereisstrongclinicalevidenceinsubgroups
of patients with depression that symptom intensity and the
course of disease are associated with elevated plasma levels
of pro-inﬂammatory mediators, including IL-1, IL-2, IL-6,
TNF, and C-reactive protein (for review, see [50]). Multiple
studies have shown that there is a decrease in Th1 mediator
levels with antidepressant treatment, indicating that one
potential mechanism of action of antidepressant treatments
is decreased inﬂammation. In a rare prospective study [51],
an increased inﬂammatory state at baseline (elevated levels
of C-reactive protein and increased capacity of leukocytes to
produce IL-1) predicted later onset of depression in elderly
individuals without a prior history of depression, suggesting
that excess inﬂammation precedes depression. It is not as yet
entirely clear how inﬂammatory cytokines aﬀect mood and
high cognitive functions.
Anotherclueforimmune-to-braincommunicationasso-
ciated with psychpathology may be gleaned from patients
with chronic neuropathic pain. Activation of phagocytic
immune cells (e.g., macrophages) around an otherwise
healthy peripheral nerve leads to the release of proin-
ﬂammatory cytokines (TNF, IL1, and IL6), as well as
other proinﬂammatory substances [52]. The inﬂammatory
response may be a link to the high prevalence of depression
among these patients.
Thus, we hypothesize that primary BBB breakdown will
enhancebraininﬂammationthroughtwomainmechanisms.
(1) In the event of a peripheral inﬂammatory response,
BBB breakdown will increase the transport of peripheral
cytokines into the brain, thus inducing the activation of
astrocytes, microglia, and recruitment of immune cells. (2)
Prolonged and pronounced BBB breakdown will directly
inducealocalinﬂammatoryresponsebyactivatingastrocytes
(as explained above) that will secrete cytokines locally.
Increased cytokine levels may also be involved in depres-
sion via their direct eﬀect on serotonin levels [53]. Inﬂam-
matory mediators may also alter network properties and
neuronalexcitabilitybychangingglutamatelevelsandaﬀect-
ing synaptic plasticity: inﬂammatory mediators can, through
activation of the kynurenine pathway, increase kynurenic
acid—an NMDA receptor antagonist, and quinolinic acid—
anNMDAreceptoragonist.Microgliaaretheonlycellsinthe
central nervous system that express the complete enzymatic
pathway required for the synthesis of quinolinic acid [54].
Therefore, inﬂammatory mediators acting on microglia will
increase the ratio of quinolinic acid to kynurenic acid,
leading to increased activation of NMDA receptors. Recent
studies further suggest that increased glutamate levels may
also activate astrocytes and microglia leading to release of
inﬂammatory mediators, causing a vicious cycle.
3.4. From BBB Breakdown via Astrocytic Transformation and
InﬂammatoryResponsetoBrainDysfunction. Ourhypothesis
directly links BBB breakdown, the consequent transforma-
tion of astrocytes and microglia, and the resultant local
inﬂammation to network dysfunction, which may underlie
psychiatric illnesses. As mentioned earlier, the dysfunction
of astrocytes and the inﬂammatory response are expected to
cause a reduction in the buﬀering of extracellular potassium
andglutamate.Togetherwithincreasedquinolinicacid,these
will act synergistically to depolarize neuronal membranes,
thus furtherallowing the activation of the voltage-dependent
NMDA receptors. While in extreme cases the excess of
NMDA receptors activation may lead to neuronal toxicity, it
is important to point out that neurotoxicity in psychiatric
disorders has not been unequivocally demonstrated. We
propose that under milder conditions, enhancing NMDA
receptors activation results in abnormal synaptic plasticity—
which refers to enhanced synaptic strength and (or) loss
of pathway speciﬁcity. Such reduced speciﬁcity is expected
to result in the activation of larger neuronal networks
in response to stimuli, Manifested as disturbed thinking
processes and extreme mood-related behavioral responses,
depending on the involved network. Under even more
extreme conditions, the activated network will be larger,
leading to epileptic activity [13] and delayed neuronal
toxicity [14].
Interestingly, a recent study demonstrated that in the
KA rat model for schizophrenia, there is suppression of
homosynaptic long-term plasticity with disturbed heterosy-
naptic depression within the hippocampus [55]. Increased
connectivity between neighboring neurons has been also
found in the valopric acid model of autism in rats [56].
The authors suggested that this local hyperconnectivity may
render cortical modules more sensitive to stimulation and,
once activated, make them more autonomous, isolated, and
more diﬃcult to command.
4.SummaryandFuturePerspectives
Figure 1summarizesthesequenceofeventsoccurringwithin
the “neurovascular unit,” which according to the proposed
hypothesis leads to network hyperconnectivity and psychi-
atric illness. According to our hypothesis, early injury to the
BBB, due to vascular or brain pathology, will disturb “blood-
brain communication” and initiate a sequence of events that
will ﬁnally result in abnormal plasticity within the neuronal
network, namely, hyperconnectivity. Our hypothesis put
together ﬁndings observed in psychiatric patients to form a
broader pathophysiological picture. These ﬁndings include,
for example, increased CSF albumin and serum S100B—
as markers for BBB breakdown, increased brain astroglial
markers within the brain—as markers for their activation,
inﬂammatory markers—the result or cause of astroglial acti-
vation, and changes in glutamate levels, neuronal connectiv-
ity, and, in some cases, neurons loss. The hypothesis further
explains the high rate of psychiatric illnesses following brain
injury, acute stress reactions, and vascular pathologies (e.g.,
systemic lupus erythematosus) which may frequently be
associated with BBB breakdown. It may also explain the
relation between the presence of peripheral inﬂammatory
process in some psychiatric patients as well as the frequentCardiovascular Psychiatry and Neurology 5
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Figure 1: The BBB Hypothesis of Psychiatric Disorders. Interactions within the neurovascular unit in the presence of abnormal blood-brain
communication. BBB breakdown results in the diﬀusion of serum proteins (e.g., albumin, see text) into the brain, activation of signaling
pathways, and inducing the transformation of astrocytes. This “reactive” glial reaction is associated with impaired extracellular homeostasis
(e.g., reduced buﬀering of extracellular potassium and glutamate) and a local inﬂammatory response (e.g., secretion of cytokines, activation
of microglia) and is enhanced in the presence of an inﬂammation in the periphery. Together, neuronal network dysfunction develops due to
pathological synaptic plasticity.
comorbidity with epilepsy—characterized by hyperexcitable
and hypersynchronized network.
Our hypothesis raises many questions regarding the
location(where?),extent(towhichmolecules?)andduration
of BBB damage suﬃcient to induce the described disease
process. We put forward testable predictions in animal
models and human patients and raise the importance of
time line, long-term, and, whenever possible, prospective
studies, to challenge the proposed hypothesis. A better
understanding of BBB damage and repair processes and
serum-born signaling molecules is essential for the iden-
tiﬁcation of new therapeutic targets. Our hypothesis calls
for the use of recently developed approaches for measuring
BBB breakdown in patients at risk for developing psychiatric
illnesses (or during the early phases of the disease). The use
of novel molecular markers for imaging brain inﬂammation
may, in the future, facilitate better understanding of their
role in diﬀerent patient populations and at diﬀerent stages
of the disease. Future studies are also needed to uncover the
interactions between BBB-mediated brain pathologies and
speciﬁc transmitter systems which have been reported to
play a role in speciﬁc psychopathologies. We further believe
that our hypothesis—if found valid—will oﬀer previously
unforeseen targets for the prevention and treatment of
psychiatric diseases. It may also explain and encourage the
use of anti-inﬂammatory agents against psychosis, at some
early stages of the disease [7–9]. Astrocytic dysfunction may
also become a promising target at some point during the
development of the disease.
In summary, the “BBB hypothesis” for impaired neu-
ronal network connectivity is based on well-described inter-
actionsbetweencomponentsatthe“neurovascularunit”and
proposes a new concept pointing to disturbed blood-brain
communication as a potentially important cause and future
target for the treatment of psychiatric disorders.
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